Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark Young
Mark Young
Intercept Pharmaceuticals
Obeticholic acid
Farnesoid X receptor
Cholesterol
Endocrinology
Internal medicine
5
Papers
123
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
2019
Scientific Reports
Jonathan D. Roth
Sanne S. Veidal
Louise K. D. Fensholdt
Kristoffer T.G. Rigbolt
R. Papazyan
Jens Nielsen
Michael Feigh
Niels Vrang
Mark Young
Jacob Jelsing
Luciano Adorini
Henrik H. Hansen
Show All
Source
Cite
Save
Citations (22)
Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
2019
International Journal of Molecular Medicine
Bin Dong
Amar B. Singh
Grace L. Guo
Mark Young
Jingwen Liu
Show All
Source
Cite
Save
Citations (6)
FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
2018
Journal of Lipid Research
Romeo Papazyan
Xueqing Liu
Jingwen Liu
Bin Dong
Emily M. Plummer
Ronald D. Lewis
J. Roth
Mark Young
Show All
Source
Cite
Save
Citations (35)
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
2017
Journal of Lipid Research
Bin Dong
Mark Young
Xueqing Liu
Amar Bahadur Singh
Jingwen Liu
Show All
Source
Cite
Save
Citations (16)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
2016
Diabetes, Obesity and Metabolism
R. Pencek
T. Marmon
J. Roth
Alexander Liberman
R. Hooshmand-Rad
Mark Young
Show All
Source
Cite
Save
Citations (44)
1